Global Neoantigen Cancer Vaccine Market

Report ID : 1117 | Published : 2021-07-26 | Pages: 140 | Format: PDF/EXCEL

Neoantigen Cancer Vaccines are vaccines that assist in boosting the immune system by using a single or several antigens. The antigens generally consist of several peptides or proteins. Neoantigens are a mutated or a new type of antigen present only in cancer cells and not in rest normal cells. Neoantigen Cancer Vaccines stimulate the new T-cell response against the mutated antigens present in the cancer cells. In 2019the neoantigen cancer vaccine market is anticipated to be US$ xx Mn and is forecasted to grow at a CAGR of xx% to reach up to US$ xx,Mn by 2030.


Neoantigen Cancer Vaccine has recorded with proven effectiveness and satisfactory results in clinical trials test of cancer treatment. Increasing cases for cancer patients across the globe and rising focus on specific & effective cancer management treatments are propelling the demand for oncology drugs and apparently boosting the market for global Neoantigen Cancer Vaccine market. Increasing emphasis on personalized cancer treatment and rising economic burden due to cancer treatment procedures has led the pharmaceutical manufacturers to invest significantly in research and development activities in order to fulfil the existing as well as latent demand for Neoantigen Cancer Vaccine.
The neoantigen cancer vaccines market is segmented on the basis of product, neovaccine type, therapy type, and region. Based on the products, the market is divided into Personalized neoantigens vaccines and Off-the-shelf Neoantigen vaccines. On the basis of neovaccine type, the market is segmented into Nucleic acid/DNA/mRNA Vaccine, Peptide Vaccines, and Dendritic Cell-based Vaccines. Based on region, the market is studied across North America, Asia-Pacific, Europe, and the Rest of World. North America is expected to dominate the market during the analysis of the forecast period.
The key players of this market include Moderna Therapeutics/Merck, Advaxis, Agenus, Genocea Biosciences Inc, Gritstone Oncology, Neon Therapeutics, Nouscom, OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, Vaccibody, Brightpath Biotherapeutics, Geneos Therapeutics, Frame Therapeutics, Immunetune, NeoPhore, and CureVac AG.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Neoantigen Cancer Vaccine Market Snapshot

Chapter 4. Global Neoantigen Cancer Vaccine Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Clinical Trial/Pipeline Analysis

4.7. Industry Analysis – Porter’s Five Forces Analysis

4.8. Technology Advancement in Neoantigen Cancer Vaccine

4.9. Key Trends in the Funding and Expansion Activities

Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis

5.1. Product Type & Market Share,2022 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2028 for the following Product:

5.2.1. Personalized neoantigens vaccines

5.2.2. Off-the-shelf Neoantigen vaccines

Chapter 6. Neoantigen Cancer Vaccine Market Segmentation 2: Neovaccine Types (Biological Platform) Estimates & Trend Analysis

6.1. Neovaccine Types (Biological Platform) Analysis & Market Share,2022 & 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2028 for the following Neovaccine Types (Biological Platform):

6.2.1. Nucleic acid/DNA/mRNA Vaccine

6.2.2. Peptide Vaccines

6.2.3. Dendritic Cell–based Vaccines

Chapter 7. Neoantigen Cancer Vaccine Market Segmentation 2: Therapy Type Estimates & Trend Analysis

7.1. Therapy Type Analysis & Market Share,2022 & 2028

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2028 for the following Therapy Type:

7.2.1. Mono Therapeutic Regimens

7.2.2. Combinatorial Regimens

Chapter 8. Neoantigen Cancer Vaccine Market Segmentation 3: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by product, 2022-2028

8.1.2. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by neovaccine types, 2022-2028

8.1.3. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by therapy types, 2022-2028

8.1.4. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by country, 2022-2028

8.1.4.1. U.S.

8.1.4.2. Canada

8.2. Europe

8.2.1. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) by product, 2022-2028

8.2.2. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by neovaccine types, 2022-2028

8.2.3. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by therapy types, 2022-2028

8.2.4. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) by country, 2022-2028

8.2.4.1. Germany

8.2.4.2. Poland

8.2.4.3. France

8.2.4.4. Italy

8.2.4.5. Spain

8.2.4.6. UK

8.2.4.7. Rest of Europe

8.3. Asia Pacific

8.3.1. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) by product, 2022-2028

8.3.2. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by neovaccine types, 2022-2028

8.3.3. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) by therapy type, 2022-2028

8.3.4. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) by country, 2022-2028

8.3.4.1. China

8.3.4.2. India

8.3.4.3. Japan

8.3.4.4. Australia

8.3.4.5. Rest of Asia Pacific

8.4. Rest of World

8.4.1. Rest of World Neoantigen Cancer Vaccine Market revenue (US$ Million) by product, (US$ Million)

8.4.2. Rest of World Neoantigen Cancer Vaccine Market revenue (US$ Million) by therapy type, (US$ Million)

8.4.3. Rest of World Neoantigen Cancer Vaccine Market revenue (US$ Million) by country, (US$ Million) 2022-2028

8.4.3.1. GCC Countries

8.4.3.2. Africa

8.4.3.3. Brazil

8.4.3.4. Rest of Latin America

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Roche

9.2.2. Medimmune

9.2.3. Moderna Therapeutics/Merck

9.2.4. Advaxis

9.2.5. Agenus

9.2.6. Genocea Biosciences Inc

9.2.7. Gritstone Oncology

9.2.8. Neon Therapeutics

9.2.9. Nouscom

9.2.10. OSE Immunotherapeutics

9.2.11. Immunovative Therapeutics

9.2.12. Medigene

9.2.13. Vaccibody

9.2.14. Brightpath Biotherapeutics

9.2.15. Geneos Therapeutics

9.2.16. Frame Therapeutics

9.2.17. Immunetune

9.2.18. NeoPhore

9.2.19. CureVac AG

9.2.20. Other Prominent Players

Global Neoantigen Cancer Vaccine Market Segmentation

Global Neoantigen Cancer Vaccine Market by Product

  • Personalized Neoantigens vaccines
  • Off-the-shelf Neoantigen vaccines

Global Neoantigen Cancer Vaccine Market Based on Neovaccine Type

  • Nucleic acid/DNA/mRNA Vaccine
  • Peptide Vaccines
  • Dendritic Cell–based Vaccines

Global Neoantigen Cancer Vaccine Market Based on Therapy Type

  • Mono Therapeutic Regimens
  • Combinatorial Regimens

Global Neoantigen Cancer Vaccine Market Based on Region

Europe Neoantigen Cancer Vaccine Market Outlook, 2019 – 2030

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Neoantigen Cancer Vaccine Market Outlook, 2019 – 2030

  • U.S.
  • Canada

Asia Pacific Neoantigen Cancer Vaccine Market Outlook, 2019 – 2030

  • China
  • Japan
  • South Korea
  • Australia & New Zealand

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients